Romidepsin targets multiple survival signaling pathways in malignant T cells

Blood Cancer Journal

Volumn 5, Issue 10, 2015, Pages

  Valdez, B C ^a   Brammer, J E ^a   Li, Y ^a   Murray, D ^b   Liu, Y ^a   Hosing, C ^a   Nieto, Y ^a   Champlin, R E ^a   Andersson, B S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DNA; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; SECRETED FRIZZLED RELATED PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; DEPSIPEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE RESPONSE; DNA METHYLATION; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; LYMPHOBLASTOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PROMOTER REGION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; UNFOLDED PROTEIN RESPONSE; UPREGULATION; CELL PROLIFERATION; DRUG EFFECTS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEPSIPEPTIDES; HUMANS; LYMPHOMA, T-CELL; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84989299928     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.83     Document Type: Article

References (35)

1. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physic-chemical and biological properties, and antitumor activity. J Antibiot 1994; 47: 301-310.
2. Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J Antibiot 1994; 47: 311-314.
3. Vinodhkumar R, Song YS, Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed Pharma 2008; 62: 85-93.
4. Mizutani H, Hiraku Y, Tada-Oikawa S, Murata M, Ikemura K, Iwamoto T et al. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. Cancer Sci 2010; 101: 2214-2219.
5. Choudhary S, Wang HC. Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. J Cancer Res Clin Oncol 2009; 135: 1601-1613.
6. Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y et al. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 2004; 3: 1397-1402.
7. Kodani M, Igishi T, Matsumoto S, Chikumi H, Shigeoka Y, Nakanishi H et al. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. Oncol Rep 2005; 13: 477-483.
8. Saijo K, Katoh T, Shimodaira H, Oda A, Takahashi O, Ishioka C. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors. Cancer Sci 2012; 103: 1994-2001.
9. Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol 2015; 170: 96-109.
10. Ravid Z, Goldblum N, Zaizov R, Schlesinger M, Kertes T, Minowada J et al. Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype. Int J Cancer 1980; 25: 705-710.
11. Smith SD, Morgan R, Link MP, McFall P, Hecht F. Cytogenetic and immunophenotypic analysis of cell lines established from patients with T cell leukemia/lymphoma. Blood 1986; 67: 650-656.
12. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 2010; 34: 364-372.
13. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U et al. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol 2015; 43: 448-461.
14. Hayakawa T, Nakayama J. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotech 2011; 2011: 129383.
15. Creppe C, Malinouskaya L, Volvert ML, Gillard M, Close P, Malaise O et al. Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell 2009; 136: 551-564.
16. Ziesché E, Kettner-Buhrow D, Weber A, Wittwer T, Jurida L, Soelch J et al. The coactivator role of histone deacetylase 3 in IL-1-signaling involves deacetylation of p65 NF-?B. Nucleic Acids Res 2013; 41: 90-109.
17. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005; 9: 809-824.
18. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 2006; 4: 563-573.
19. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 2010; 70: 4470-4480.
20. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002; 277: 10244-10250.
21. Kohno K, Normington K, Sambrook J, Gething MJ, Mori K. The promoter region of the yeast KAR2 (BiP) gene contains a regulatory domain that responds to the presence of unfolded proteins in the endoplasmic reticulum. Mol Cell Biol 1993; 13: 877-890.
22. Ellgaard L, Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep 2005; 6: 28-32.
23. Ron D, Habener J. CHOP a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominantnegative inhibitor of gene transcription. Genes Dev 1992; 6: 439-453.
24. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013; 1833: 3460-3470.
25. Cox JS, Shamu CE, Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 1993; 73: 1197-1206.
26. Muro I, Fang G, Gardella KA, Mahajan IM, Wright CW. The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways. Cell Cycle 2014; 13: 1918-1927.
27. Lento W, Congdon K, Voermans C, Kritzik M, Reya T. Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol 2013; 5: a008011.
28. Brantjes H, Barker N, van Es J, Clevers H. TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol Chem 2002; 383: 255-261.
29. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627-2634.
30. Arend RC, Londoño-Joshi AI, Straughn Jr JM, Buchsbaum DJ. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol 2013; 131: 772-779.
31. Wang HQ, Jin JJ, Wang J. Matrine induces mitochondrial apoptosis in cisplatinresistant non-small cell lung cancer cells via suppression of β-catenin/surviving signaling. Oncol Rep 2015; 33: 2561-2566.
32. Steinhusen U, Badock V, Bauer A, Behrens J, Wittman-Liebold B, Dörken B et al. Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 2000; 26: 16345-16353.
33. Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Expert Opin Investig Drugs 2009; 18: 1169-1181.
34. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
35. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673-691.